Condition: Pancreatic Ductal Adenocarcinoma · Borderline Resectable Pancreatic Adenocarcinoma · Locally Advanced Pancreatic Adenocarcinoma · Sponsor: PanTher Therapeutics
This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).
This description comes directly from the study's public registry record.
Chelsea Reinhold · 2032419779 · ClinOps@panthertx.com
Always discuss trial participation with your own doctor first.
| Hoag Memorial Hospital Presbyterian | Newport Beach, California, United States | Recruiting |
| Karmanos Cancer Institute | Detroit, Michigan, United States | Recruiting |
| Northwell Health Zuckerberg Cancer Center | Lake Success, New York, United States | Recruiting |
| University of Texas Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Virginia Mason Medical Center | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06673017